Patient P-01556

Synthetic patientNBL-101 · Day 115 · 45–54 · M · baseline S14Steering view · 3D Open companion preview

Therapy response

Improving

Tolerance

Stable

GI state

Improving

Inflammatory state

Stable

Nutritional resilience

Improving

Discontinuation risk

62%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 49 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 52 SC-12 recommended — Supportive Compound SC-12
Day 53 Patient accepted — Started SC-12 in the companion
Day 58 GI-04 recommended — GI Support Protocol GI-04
Day 59 Patient accepted — Started GI-04 in the companion
Day 59 No meaningful change — Supportive Compound SC-12
Day 67 GI symptom burden −33% vs expected — GI Support Protocol GI-04
Day 73 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 49.

Primary contributors, last 14 days

GI instability-8
Nutritional resilience+8
Inflammatory activity-2
Toxicity+2

What helped?

Supportive Compound SC-12Day 52
Result: no meaningful change
GI Support Protocol GI-04Day 58
Result: symptom burden −33%

LIFE OS recommendation

Dietary Support Protocol NP-02

56%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

49.5/100

worsening · +3.9 vs previous 14 d

Toxicity

Blood

40.4/100

worsening · +1.9 vs previous 14 d

Sleep quality

Wearable

37.3/100

stable · +0.6 vs previous 14 d

Energy level

Daily log

3.1/10

worsening · -0.2 vs previous 14 d

Stress level

Daily log

5.4/10

worsening · +0.3 vs previous 14 d

Steps

Wearable

6,845

stable · -216 vs previous 14 d

Adherence

Companion

51.3 %

worsening · -3.9 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards restoration · 31 from the failing basin, 56 from restoration.

Would help

ME-01 Monitoring Escalation
100% improved among 77 similar · onset 3 d · confidence 67%
NP-02 Dietary Support Protocol
63% improved among 64 similar · onset 10 d · confidence 67%
CR-01 Clinician Review
100% improved among 8 similar · onset 5 d · confidence 67%

Would not help

SC-12 Supportive Compound
already tried, no meaningful change
Keep histamine low
GI +6.3 next day on high-intake days · n 25
Keep fat low
GI +5.9 next day on high-intake days · n 18
Keep simple carbs low
GI +5.3 next day on high-intake days · n 18

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Histamine load
+6.3detractor · 95%
Dietary fat load
+5.9detractor · 95%
Simple carbohydrates
+5.3detractor · 95%
Insoluble fibre
+4.1detractor · 94%
Alcohol
+3.4detractor · 72%
Spicy / capsaicin
-0.7no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↓85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 53
- WearableHRV 37 ms, trending down
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 32/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Drug metabolism and exposure ↑55
- DNADPYD *2A → slower clearance
- BloodToxicity index 40
Mucosal barrier integrity ↓50
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 50 and rising
Autonomic recovery ↑25
- WearableResting HR 79 bpm

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
DPYD *2A heterozygous
Slower drug clearance
CYP2D6 Intermediate metabolizer
Expected exposure

Microbiome

Shannon diversity 2 · butyrate capacity 32/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 35 ms
Sleep: 6.4 h
Steps: 6,883
Resting HR: 77 bpm

Daily log: GI score 50, nutritional resilience 48, adherence 51.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01377	23%	S11	AD-05	no change	42
P-01350	23%	S19	BR-03	no change	34
P-01708	34%	S07	CR-01	improved	59
P-01371	32%	S06	CR-01	improved	63
P-01696	31%	S20	CR-01	improved	59
P-01388	30%	S17	CR-01	improved	59
P-01835	30%	S17	CR-01	improved	56
P-01442	29%	S13	CR-01	improved	61
P-01877	28%	S01	CR-01	improved	67
P-01430	25%	S05	CR-01	improved	54
P-01342	23%	S11	DT-01	improved	48
P-01611	60%	S14	GI-04	improved	44